These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Intrinsic sympathomimetic activity: clinical fact or fiction? Taylor SH Am J Cardiol; 1983 Nov; 52(9):16D-26D. PubMed ID: 6139009 [TBL] [Abstract][Full Text] [Related]
9. Cetamolol: cardiovascular effects of a new cardioselective beta-adrenoceptor blocker possessing partial agonistic activity and lacking membrane-stabilizing activity. Beaulieu G; Grimes D; Muirhead C; Oshiro G Can J Physiol Pharmacol; 1984 Jun; 62(6):610-6. PubMed ID: 6146394 [TBL] [Abstract][Full Text] [Related]
10. Influence of beta-blockade with beta-1-selectivity or intrinsic sympathomimetic activity on some cardiorespiratory responses to exercise. Yonga GO; Oyuga HW; Njeru EK East Afr Med J; 1993 Jul; 70(7):405-8. PubMed ID: 7904931 [TBL] [Abstract][Full Text] [Related]
11. Cardioselective and nonselective beta-adrenoceptor blocking drugs in hypertension: a comparison of their effect on blood pressure during mental and physical activity. Floras JS; Hassan MO; Jones JV; Sleight P J Am Coll Cardiol; 1985 Jul; 6(1):186-95. PubMed ID: 2861218 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)]. Lemmer B Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492 [TBL] [Abstract][Full Text] [Related]
13. Cardiac effects of beta-adrenoceptor blockade with intrinsic sympathomimetic activity during submaximal exercise. Ades PA Br J Clin Pharmacol; 1987; 24 Suppl 1(Suppl 1):29S-33S. PubMed ID: 2894223 [TBL] [Abstract][Full Text] [Related]
14. Pharmacology of combined alpha-beta-blockade. I. Louis WJ; McNeil JJ; Drummer OH Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889 [TBL] [Abstract][Full Text] [Related]
15. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431 [TBL] [Abstract][Full Text] [Related]
16. Comparison of beta-adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol). Erikssen J; Thaulow E; Mundal R; Opstad P; Nitter-Hauge S Br J Clin Pharmacol; 1982; 13(Suppl 2):201S-209S. PubMed ID: 6125171 [TBL] [Abstract][Full Text] [Related]
17. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension. Man in't Veld AJ; Schalekamp MA Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of beta 1-selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug. Frishman WH Am J Cardiol; 1987 May; 59(13):33F-37F. PubMed ID: 2883876 [TBL] [Abstract][Full Text] [Related]
19. Plasma insulin levels and beta-adrenoceptor antagonists. The effects of cardioselective and non-cardioselective beta-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on basal insulin level and insulin level after glucose stimulation in normoglycemic dogs. Conca W; Beck A; Bacher S; Raberger G Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):63-6. PubMed ID: 6126816 [TBL] [Abstract][Full Text] [Related]
20. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. McDevitt DG; Brown HC; Carruthers SG; Shanks RG Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]